

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



## ASCENTAGE PHARMA GROUP INTERNATIONAL

亞盛醫藥集團

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6855)

### Voluntary Announcement

#### Ascentage Pharma to Present Latest Results from Three Preclinical Studies at 2023 American Association for Cancer Research Annual Meeting

Ascentage Pharma Group International (the “Company” or “Ascentage Pharma”) is pleased to announce that the latest results from three preclinical studies of the Company’s commercialized novel class 1 third-generation BCR-ABL inhibitor olverembatinib (HQP1351) and two key assets of Ascentage Pharma’s apoptosis-targeting pipeline, the Bcl-2 inhibitor lisaftoclax (APG-2575) and the MDM2-p53 inhibitor alrizomadlin (APG-115), have been selected for presentations at the 2023 American Association of Cancer Research Annual Meeting (AACR 2023). These results provide key findings that will support continued advances in the development of innovative therapeutics. Abstracts featuring these results have already been published on AACR’s official website.

The AACR annual meeting is one of the world’s largest and longest-standing scientific gatherings in the field of cancer research. Covering some of the most cutting-edge advances in all the areas of oncology research and innovation, the annual event attracts tremendous interest from the global cancer research community. This year’s AACR annual meeting will be held from April 14 to April 19, 2023, in Orlando, Florida, USA.

The abstracts of Ascentage Pharma’s three preclinical studies are as follows:

#### **Olverembatinib (HQP1351)**

#### **Olverembatinib (HQP1351) enhances antitumor effects of immunotherapy in renal cell carcinoma (RCC)**

- Abstract number: 5071
- Track: Immunology
- Session Title: Combination Immunotherapies 1
- Session Time: Tuesday, April 18, 2023, 1:30 PM-5:00 PM, EDT/Wednesday, April 19, 2023, 1:30 AM-5:00 AM, Beijing time

Our results suggest that combining olverembatinib with a checkpoint inhibitor (CPI) confers synergistic antitumor effects in an RCC cancer mouse model by targeting tumor growth, angiogenesis, and immune regulation. This novel combination may provide an alternative approach to enhance treatment effects with CPIs in renal cancers.

## **Olverembatinib (HQP1351) plus LISAFTOCLAX (APG-2575)**

### **Combination of olverembatinib (HQP1351) with BCL-2 inhibitor lisaftoclax (APG-2575) overcomes resistance in gastrointestinal stromal tumors (GISTs)**

- Abstract number: 1631
- Track: Experimental and Molecular Therapeutics
- Session Title: Novel Antitumor Agents 3
- Session Time: Monday, April 17, 2023, 9:00 AM-12:30 PM, EDT/Monday, April 17, 2023, 9:00 PM-00:30 AM, Beijing time

Our results demonstrate that olverembatinib and Bcl-2 inhibitor lisaftoclax have synergistic antitumor effects in imatinib-resistant GIST. Considering that the resistance mechanisms are similar for most tyrosine kinase inhibitors (TKIs), this novel dual approach may have the potential for treating patients with GISTs whose disease has progressed after treatment with imatinib or other TKIs.

## **Alrizomadlin (APG-115)**

### **MDM2 inhibitor alrizomadlin (APG-115) promotes antitumor activity of mitogen-activated protein kinase (MAPK) inhibitors in uveal melanoma**

- Abstract number: 1632
- Track: Experimental and Molecular Therapeutics
- Session Title: Novel Antitumor Agents 3
- Session Time: Monday, April 17, 2023, 9:00 AM-12:30 PM, EDT//Monday, April 17, 2023, 9:00 PM-00:30 AM, Beijing time

Our results demonstrate the potential utility of combining alrizomadlin with MAPK pathway inhibitors to treat patients with uveal melanoma.

**Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited:** We cannot guarantee that we will be able to obtain further approval for, or ultimately market, APG-2575 and APG-115 successfully.

By order of the Board  
**Ascentage Pharma Group International**  
**Dr. Yang Dajun**  
*Chairman and Executive Director*

Suzhou, People's Republic of China, March 15, 2023

*As at the date of this announcement, the Board of Directors of the Company comprises Dr. Yang Dajun as Chairman and executive Director, Dr. Wang Shaomeng and Dr. Lu Simon Dazhong as non-executive Directors, and Mr. Ye Changqing, Dr. Yin Zheng, Mr. Ren Wei and Dr. David Sidransky as independent non-executive Directors.*